Back to top

earnings-consensus: Archive

Zacks Equity Research

Wall Street Analysts See a 31.98% Upside in Tapestry (TPR): Can the Stock Really Move This High?

The consensus price target hints at a 32% upside potential for Tapestry (TPR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

TPRNegative Net Change

Zacks Equity Research

Wall Street Analysts Think Disc Medicine, Inc. (IRON) Could Surge 64.74%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 64.7% in Disc Medicine, Inc. (IRON). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

IRONNegative Net Change

Zacks Equity Research

Does LifeStance Health (LFST) Have the Potential to Rally 25.94% as Wall Street Analysts Expect?

The consensus price target hints at a 25.9% upside potential for LifeStance Health (LFST). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

LFSTPositive Net Change

Zacks Equity Research

Wall Street Analysts Predict a 26.89% Upside in TKO Group (TKO): Here's What You Should Know

The consensus price target hints at a 26.9% upside potential for TKO Group (TKO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

TKONegative Net Change

Zacks Equity Research

How Much Upside is Left in Anterix (ATEX)? Wall Street Analysts Think 61.01%

The consensus price target hints at a 61% upside potential for Anterix (ATEX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

ATEXNegative Net Change

Zacks Equity Research

Wall Street Analysts Predict a 36.78% Upside in Mercury Systems (MRCY): Here's What You Should Know

The mean of analysts' price targets for Mercury Systems (MRCY) points to a 36.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

MRCYNegative Net Change

Zacks Equity Research

Wall Street Analysts Predict a 42.25% Upside in MYR (MYRG): Here's What You Should Know

The consensus price target hints at a 42.3% upside potential for MYR (MYRG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

MYRGNegative Net Change

Zacks Equity Research

Wall Street Analysts Think PDD Holdings Inc. Sponsored ADR (PDD) Could Surge 28.92%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 28.9% in PDD Holdings Inc. Sponsored ADR (PDD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

PDDNegative Net Change

Zacks Equity Research

Wall Street Analysts See a 39.78% Upside in Tactile Systems Technology (TCMD): Can the Stock Really Move This High?

The mean of analysts' price targets for Tactile Systems Technology (TCMD) points to a 39.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

TCMDNegative Net Change

Zacks Equity Research

Wall Street Analysts Think Montes Archimedes Acquisition (ROIV) Could Surge 29.62%: Read This Before Placing a Bet

The mean of analysts' price targets for Montes Archimedes Acquisition (ROIV) points to a 29.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

ROIVNegative Net Change